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Purpose: To examine the effects of neuroprotectin D1 (NPD1), a stereospecific derivative of docosahexaenoic acid, on
choroidal neovascularization (CNV) in a laser-induced mouse model. Specifically, this was assessed by clinically grading
laser-induced lesions, measuring leakage area, and volumetrically quantifying vascular endothelial cell proliferation.
Methods: C57Bl/6 mice were treated with vehicle control or NPD1, and choroidal neovascularization was induced by
laser rupture of Bruch's membrane; treatment was administered throughout the first week of recovery. One and two weeks
after CNV induction, fundus fluorescein angiography was performed. Angiograms were clinically graded to assess leakage
severity, while leakage area was measured by image analysis of angiograms. Proliferation of vascular endothelial cells
was evaluated volumetrically by three-dimensional laser confocal immunofluorescent microscopy of cytoskeletal, nuclear,
and endothelial cell markers.
Results: At seven days after CNV induction, NPD1-treated mice had 60% fewer clinically relevant lesions than controls,
dropping to 80% fewer by 14 days. NPD1 mice exhibited 25% smaller leakage area than controls at 7 days and 44%
smaller area at 14 days. Volumetric immunofluorescence revealed 46% less vascular endothelial cell volume in 7-day
NPD1-treated mice than in 7-day controls, and by 14 days NPD1 treatment was 68% lower than controls. Furthermore,
comparison of 7- and 14-day volumes of NPD1-treated mice revealed a 50% reduction at 14 days.
Conclusions: NPD1 significantly inhibits choroidal neovascularization. There are at least two possible mechanisms that
could explain the neuroprotective action of NPD1. Ultimately, nuclear factor-κB could be inhibited with a reduction in
cyclooxygenase-2 (COX-2) to reduce vascular endothelial growth factor (VEGF) expression, and/or activation of the
resolution phase of the inflammatory response/survival pathways could be upregulated. Moreover, NPD1 continues to be
effective after treatment is concluded, suggesting sustained protection and highlighting the potential applicability of this
lipid mediator in preventing or ameliorating endothelial cell growth in pathoangiogenesis.
Neovascularization at or near the retina/vitreous interface
is characteristic of retinopathy of prematurity and diabetic
retinopathy, while new vessel growth from the choroid into
the retina occurs in age-related macular degeneration (AMD).
Choriocapillaris endothelial cell proliferation is stimulated
when Bruch’s membrane is damaged. In hypoxic/damaged
regions, endothelial cells divide, align, tubularize, and lay
down new basement membrane to form functioning vessels.
During  this  process,  newly  formed  capillaries  leak  and
displace  surrounding  cells  [1].  Ramification  of  these  new
vessels through the retinal pigment epithelial (RPE) cell layer
into the subretinal space may lead to retinal detachment and
hemorrhaging, inducing photoreceptor cell death and causing
loss  of  the  central  visual  field.  This  choroidal
neovascularization  (CNV)  is  characteristic  of  wet  or
exudative  AMD.  While  the  physiologic,  cellular,  and
biochemical events leading to AMD are not well defined,
inflammation has been shown to be an early event [2].
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The pro-inflammatory cytokines tumor necrosis factor α
(TNF-α) and interleukin (IL)-1β increase the permeability
(i.e., vascular leakage) of the pericyte/endothelial cell unit
through a phospholipase A2 (PLA2)-dependent mechanism
[3]. Activation of the pro-inflammatory transcription factor
nuclear  factor  κB  (NF-κB)  is  a  common  downstream
component  of  both  TNF-α  and  IL-1β  pathways.  Our
laboratory  has  shown  in  retinal  choroid  cells  that  IL-1β-
induced  NF-κB  activity  ultimately  leads  to  upregulated
vascular endothelial growth factor (VEGF) expression [4].
VEGF  controls  both  physiologic  and  pathological
angiogenesis  [5],  and  increased  expression  of  VEGF  is
associated  with  AMD  pathology  [6].  VEGF-neutralizing
agents, primarily as an antibody-based approach, have been
successful in reducing angiogenesis in animal models [7], and
pharmacological intervention, based on these principles is
now being used in the treatment of AMD [8]. Thus, one
approach for managing AMD is inhibition of the signaling that
triggers vascularization [9], although this is a secondary event
resulting from primary insults. However, a second possibility
for intervention involves the upstream regulation of VEGF-
triggering  events,  including  upregulation  of  protective
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320signaling that can suppress/attenuate the initial induction of
the pro-angiogenic pathway.
Lipid mediators have key functions in the cell-to-cell
signaling of the retina and in other parts of the nervous system,
and these mediators display both pro- and anti-inflammatory
bioactivity. For example, the ω-6 arachidonic acid derivatives
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) elicit pro-
inflammatory responses by increasing the production of IL-6.
Conversely,  the  ω-3  polyunsaturated  fatty  acid  (PUFA)
docosahexaenoic  acid  (DHA)  is  anti-inflammatory  [10];
decreases cytokines, adhesion molecules, and reactive oxygen
species;  and  regulates  cyclooxygenase-2  (COX-2)  activity
[11].  PUFAs,  especially  DHA  and  arachidonic  acid,  are
abundant  in  retina  where  they  become  concentrated  in
photoreceptor and RPE cells [12] and the retinal vasculature
[13]. If released from the membranes of these cells by PLA2
under conditions of stress, PUFAs become precursors for a
variety  of  mediators  involved  in  the  resolution  of
inflammation.  These  include  prostaglandins,  lipoxins,
resolvins [11], and the docosanoid neuroprotectin D1 (NPD1;
10R, 17S-dihydroxy-docosa-4Z, 7Z, 11E, 13E, 15Z, 19Z-
hexaenoic acid) [14-16]. Connor et al. [17] have shown that
NPD1, resolvin D1, and resolvin E1 (all derivatives of ω-3
PUFAs)  suppress  angiogenesis,  and  Szymczak  et  al.  [18]
demonstrated  that  this  particular  process  is  mediated  by
upregulation of COXs. Because the ω-3 PUFAs inhibit major
pro-angiogenic processes in endothelial cells [18] but do not
affect  VEGF  [17],  ω-3  PUFA  protection  may  involve  a
VEGF-independent mechanism.
DHA  is  enriched  and  selectively  retained  in
photoreceptor cells where it is incorporated into synapses and
outer segment disk membranes [19,20]. Reduced retinal DHA
leads  to  rod-based  visual  dysfunction  [21],  while  an
abnormally  low  amount  of  brain  DHA  promotes  learning
deficits [22]. In addition, DHA is protective of neuronal and
RPE cells undergoing oxidative stress [15,16,23-25] and of
brain neurons during transient, focal, cerebral ischemia [26].
NPD1 is a DHA-derived stereoselective mediator that rescues
RPE cells and bestows neuroprotection in a model of stroke
[26,27]. Moreover, NPD1 protects against neovascularization
in  a  mouse  model  of  oxygen-induced  retinopathy  [17].
Therefore,  NPD1  may  prove  effective  in  depressing
endothelial  cell  growth  from  the  choriocapillaris  into  the
photoreceptor layer in a laser-induced mouse model of CNV.
However, while vascular proliferation is a hallmark of several
degenerative  diseases  in  retina,  laser-induced  choroidal
neovascularization is an experimental approach to produce an
injury rather than a model for AMD.
In the present study we evaluated the effect of NPD1 on
the growth of endothelial cells from the choriocapillaris into
the subretinal space and the subsequent leakage in the retina
of these new pathogenically formed vessels.
METHODS
All  animal  experiments  conformed  to  the  Association  for
Research in Vision and Ophthalmology (ARVO) statement
for the Use of Animals in Ophthalmic and Vision Research
and were approved by the Institutional Animal Care and Use
Committee for the Louisiana State University Health Sciences
Center  (LSUHSC).  Male  C57Bl/6  mice  (25–30  g)  were
obtained from Charles River Laboratories (Wilmington, MA)
and maintained in the LSUHSC animal colony on a 12 h:12 h
light–dark  cycle  (0600  h  on;  1800  h  off)  at  an  average
illumination  of  20  lux  (bedding  level  in  cage  center  on
ventilation rack). Animals were fed normal mouse chow and
supplied with water ad libitum.
Prior to laser treatment and during subsequent times when
retinal imaging occurred, 70 mice were anesthetized with
intraperitoneal (i.p.) injections of 100 mg/kg ketamine and
10 mg/kg xylazine (Vedco Inc., St. Joseph, MO). Pupils were
dilated  with  1%  Tropicamide  Ophthalmic  Solution
(Tropicacyl®; Akorn, Inc., Buffalo Grove, IL), and contact
lenses  (Veterinary  Specialty  Products,  Whitechurch,  UK)
were  used  to  improve  image  quality  and  prevent  corneal
dessication. NPD1 (1 mg/ml in 97.5% ethanol; RX-20001;
Resolvyx Pharmaceuticals, Bedford, MA) was injected i.p.
(200 µl; 114 µg/kg +1.4% ethanol in saline) 1 h before and 1,
3, 5, and 7 days after laser treatment. Control mice were
treated similarly but only received 1.4% ethanol in saline
(vehicle). Mice were anesthetized and their pupils dilated for
laser treatment.
Laser choroidal neovascularization: Laser treatment was
performed on each mouse retina. A coverslip, floated on a
drop of 2.5% methylcellulose on the mouse cornea, served to
subtract the optics of the cornea and lens for optimal viewing
of the retina and placement of the laser lesions. To trigger the
onset of retinal CNV, three 532-nm diode laser spots (lesion
diameter 50 µm; duration 100 ms; energy 150 mW) were
applied to each fundus with a Novus Spectra ophthalmic laser
(Lumenis, Inc., Santa Clara, CA) mounted on a slit lamp
(Model SL-07; Topcon, Inc.,Tokyo, Japan). These lesions
were  placed  between  retinal  vessels  two  to  three  disc
diameters from the optic nerve in an isosceles triangle with
the apex in the superior retina, making it possible to identify
each lesion in the flatmount preparations during analysis. Our
inclusion criteria were the formation of a bubble immediately
after  laser  application  and  the  absence  of  subretinal
hemorrhage. Lesions violating these criteria were excluded
from the study. After full recovery from anesthesia, mice were
returned to the animal colony.
Angiography: In vivo fundus fluorescein angiography of
CNV lesions was conducted using a SPECTRALIS® high-
resolution,  spectral  domain  optical  coherence  tomography
(HRA+OCT) imaging system (Heidelberg Engineering, Inc.,
Vista,  CA),  which  uses  high-resolution  spectral  domain
optical coherence tomography and a confocal scanning laser
ophthalmoscope.
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Pharmaceuticals, Rancho Cucamonga, CA) delivered once
i.p., initiated a two-image leakage analysis protocol, which
was performed at post-laser treatment days 7 and 14. After
fluorescein injection, early and late-phase fundus angiograms
were  obtained  at  an  interval  of  5  min.  The  early  phase
angiogram was obtained 1 min after injection; timing started
immediately after fluorescein injection.
Leakage grading and area analysis: The leakage of each
CNV lesion was graded by a retina specialist according to the
method described by Marneros et al. [28]. Briefly, early and
late-phase angiograms were compared to determine whether
the lesion exhibited bright hyperfluorescence and late leakage
beyond treated areas (Grade 2b); hyperfluorescence and late
leakage  (Grade  2a);  hyperfluorescence  without  leakage
(Grade 1); or no hyperfluorescence (Grade 0; Figure 1). Only
lesions with a leakage of Grade 2b were considered clinically
significant. Additionally, the leakage area for each lesion was
measured using a custom programmed macro for National
Institutes of Health (NIH) ImageJ software. Early and late-
phase angiograms of each lesion were presented serially to an
observer who outlined each fluorescent cloud, using a Wacom
drawing  tablet  interface  (Wacom  Technologies,  Corp.,
Vancouver, WA); treatment groups and recovery durations
were randomized and blinded from the observer. The software
recorded  treatment,  angiogram  phase,  and  leakage  area
values.
Immunofluorescence and volumetric analysis: At 7 and
14  days  after  laser  application,  mice  were  sacrificed  by
cervical dislocation, eyes were enucleated, and corneas slit.
Anterior segments and retinas were removed to create an eye
cup  following  overnight  fixation  (4  °C)  in  4%
paraformaldehyde (Electron Microscopy Sciences, Hatfield,
PA) in phosphate buffered saline (PBS, pH 7.4; Grand Island
Biologic Company, St. Louis, MO). Eye cups were washed in
PBS (3×10 min), permeabilized, and then blocked with 2%
normal donkey serum (Sigma, St. Louis, MO) and 1% Triton-
X  (Invitrogen)  in  PBS  (3×10  min).  Eye  cups  were  then
incubated  (overnight,  4  °C)  with  Isolectin  B4,  Griffonia
simplicifolia,  conjugated  to  AlexaFluor®  568  (25  µg/ml;
Invitrogen),  phalloidin  conjugated  to  AlexaFluor®  488  (5
units/ml;  Invitrogen),  and  Hoechst  33258  (20  µg/ml;
Invitrogen) to detect endothelial cells, cytoskeleton (f-actin),
and nuclei, respectively. Following a final wash with PBS,
labeled eye cups were flattened with four peripheral radial cuts
and  coverslipped  with  ProLong  Gold  antifade  medium
(Invitrogen). Flatmounts were imaged on a Zeiss LSM-510
Meta laser confocal microscope with a 40× oil-immersion
objective (Zeiss Plan-NEOFLUAR 40×/1.3 Oil DIC; Zeiss,
Thornwood, NY). Optical slice thickness for all fluorophores
was 0.9 µm. Image resolution was set to 0.45 µm per pixel.
Cubic voxel dimensions were ensured by setting the z-step
interval to 0.45 µm. Visualization of the fluorescent signal
was achieved as follows (excitation; emission; pinhole Ø):
Hoechst  33258  (405  nm;  420–490  nm;  1.27  Airy);
AlexaFluor®  488  (488  nm;  505–550  nm;  1.00  Airy);
AlexaFluor® 568 (543 nm; 560–615 nm; 0.94 Airy). For each
lesion, an image stack was collected from the RPE surface
through the choroid; the upper and lower boundaries in the z-
direction  were  adjusted  to  include  all  possible  isolectin
signals. Volumetric analysis of these three-dimensional (3D)
images was done using a custom programmed plug-in for NIH
ImageJ software. The image stack histogram of the target
channel (isolectin) was normalized, ensuring inclusion of low
intensity  signals.  Noise  generated  by  normalization  was
smoothed using a modified 3D median filter operation, which
better  preserved  the  true  3D  signal  over  the  noise.  After
median filtering the target channel was segmented with an
adaptive 3D thresholding algorithm and binarized. Inclusion
of a pixel was calculated based on continuity comparison to
pixels contained within a user-defined 3D radius. The volume
was  then  calculated  by  summing  the  number  of  included
pixels and multiplying by the x, y, and z dimensions of the
voxel unit.
Figure 1. Fundus angiography illustrating the grading scale used for leakage cloud classification. Following an intraperitoneal fluoroscein
injection, angiograms were obtained after 1 and 6 min to determine the rate of leakage. Retinal images were collected and graded from control
and neuroprotectin D1 (NPD1)-treated animals at 7 and 14 days following laser treatment. The terms Grade 0, Grade 1, Grade 2a, and Grade
2b are defined as follows: Grade 0 (D), no hyperfluorescence; Grade 1 (C), hyperfluorescence without leakage; Grade 2a (B), hyperfluorescence
and late leakage; Grade 2b (A), bright hyperfluorescence and late leakage beyond treated areas.
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322Statistics: All statistical analyses of clinical grading and
leakage area were done using the statistical analysis software,
SAS v9.1 (SAS Institute Inc., Cary, NC). For clinical grading,
three CNV lesions per eye were induced by laser in 70 mice
(40 controls; 30 NPD1). Of the 420 lesions, only one control
lesion was rejected due to hematoma (see Laser choroidal
neovascularization  section).  Cataracts  developed  in  seven
eyes  (six  control;  one  NPD1),  preventing  angiographic
analysis. Before the day 7 angiograms, two control-treated
mice died and one additional control mouse died before the
day  14  angiography.  All  lesions  within  an  animal  were
tabulated by grade category and distinct treatment–recovery
interactions to create a frequency table with 540 observations:
control-7d (38 mice, 209 lesions), NPD1–7d (30 mice, 177
lesions), control-14d (37 mice, 203 lesions), NPD1–14d (30
mice, 177 lesions). Distributions of clinical grades were fit to
the  generalized  logit  model  by  logistic  regression,  and
individual treatments were contrasted using the asymptotic
chi-square distribution of the Wald statistic (n=766, α=0.05).
Leakage area data were fit to a general linear model by the
least-squares method and compared by Analysis of Variance
(ANOVA):  control-7d  n=47,  NPD1–7d  n=56,  control-14d
n=47,  NPD1–14d  n=56,  α=0.05.  Only  lesions  having
angiograms at both 7 days and 14 days were included, and the
late-phase leakage was modeled as a function of treatment,
recovery duration, and early phase leakage. Least-squares-
adjusted means and standard error were calculated from the
model  and  used  for  data  representation.  CNV-complex
volumes  were  compared  by  one-way  ANOVA  using
Microsoft  Excel  2007  (Redmond,  WA):  control-7d  n=7,
NPD1–7d n=7, control-14d n=7, NPD1–14d n=7, α=0.05.
RESULTS
Neuroprotectin  D1  reduces  fluorescein  leakage  of  laser-
induced choroidal neovascularization lesions: CNV leakage
in NPD1-treated and vehicle-treated mice was assessed by
fluorescein  angiography  [28].  The  distribution  of  lesion
grades was plotted for each treatment at 7 and 14 days post
laser  (Figure  2).  In  vehicle-treated  mice,  the  duration  of
recovery following laser CNV initiation did not affect leakage
severity.  Treatment  with  NPD1,  however,  resulted  in  a
difference  in  leakage  grade  distribution.  The  leakage
distribution at day 14 was skewed toward a lower severity
Figure  2.  Analysis  of  leakage  clouds
from  retinas  of  control  and
neuroprotectin  D1  (NPD1)-treated
animals at 7 and 14 days following laser
treatment.  A:  Comparison  of  the
frequency  of  occurrence  of  leakage
grades  7  days  after  laser  damage  in
control  and  NPD1-treated  retinas,
illustrating a significant shift in NPD1
retinas away from the Grade 2b lesions
of controls into grades of lesser damage.
B:  A  similar  comparison,  14  days
following  laser  treatment,  showing  a
continual shift from Grade 2b lesions
toward  Grades  0,  1,  and  2a  and  a
reduction  of  leakage  from  the  NPD1
treatment.  Asterisks  denote  level  of
statistical significance as compared to
vehicle (*** p<0.001).
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323when compared with the day 7 distribution (Figure 2A,B).
CNV leakage at 7 days demonstrated remarkable differences
in grade distributions between treatments. Mice treated with
the  vehicle  had  43%  more  severe  Grade  2b  leakage  than
NPD1-treated mice, while less severe Grade 1 leakage in
NPD1-treated mice was over fivefold higher than in vehicle-
treated mice (Figure 2A). This trend continued at 14 days of
recovery, with NPD1-treated lesions exhibiting twofold and
threefold  higher  levels  of  Grade  1  and  Grade  0  leakage,
respectively,  and  vehicle-treated  lesions  having  fivefold
higher Grade 2b leakage (Figure 2B).
Treatment  comparison  of  clinically  relevant  leakage
revealed that NPD1-treated mice had 60% and 80% fewer
relevant lesions than vehicle-treated mice at 7 and 14 days
recovery,  respectively  (Figure  3A).  Additionally,  both
treatment  groups  demonstrated  a  decrease  in  clinically
relevant leakage as recovery duration increased. While the
group treated with vehicle exhibited a 24% further reduction
in relevant lesions between days 7 and 14 after laser initiation
of  CNV,  the  NPD1-treated  animals  had  a  much  larger
reduction (63%).
The fluorescein leakage of each lesion was measured in
early and late angiograms, and the leakage area was compared
using a general linear model (see Methods) at 7- and 14-day
recovery durations. Comparisons of lesions in NPD1-treated
animals with those of control mice are plotted in Figure 3B.
After 7 days of recovery, the leakage area had been reduced
by 25% in the NPD1 group, and by 14 days NPD1 reduced
leakage by 44%. Unlike the grade distributions, increased
recovery duration alone did not reduce leakage, as seen by the
comparison of 7- and 14-day leakages in vehicle-treated mice.
With NPD1 treatment, however, increased recovery reduced
7-day leakage by 19%.
Endothelial cell proliferation at lesion sites is reduced with
neuroprotectin D1 treatment: Figure 4A illustrates maximum
projection views of a typical 7-day control lesion in which the
green cytoskeleton (f-actin), blue nuclei, and red endothelial
cell channels are separated. The site of the laser lesion is
apparent in the green cytoskeleton channel, and extensive
endothelial cell ramification is evident in the red channel. The
merged image represents the superimposition of these three
channels, illustrating one layer within the confocal image
stack. While the initial laser lesion was 50 µm, the lateral
extent of endothelial cells outward from the lesion at 7 days
approached 200 µm. Neovascularization occurred near the
upper  surface  in  the  lateral  views  of  the  stack,  which
Figure  3.  Angiographic  analysis  of
choroidal  neovascularization  (CNV)-
associated leakage clouds. A: The graph
represents the frequency of occurrence
of  clinically  relevant  lesions.  The
percent  occurrence  of  only  lesions
considered  clinically  analogous  to
human  lesions  are  shown.  This
comparison of lesions from control and
neuroprotecin  D1  (NPD1)-treated
animals  at  7  and  14  days  post-laser
treatment  (from  Figure  2)  shows  an
approximate reduction in occurrence of
>40% when NPD1 retinas are compared
to controls. B: The graph represents the
leakage  cloud  areas  from  all  laser
lesions.  Following  administration  of
fluorescein  (intraperitoneal),  the
resulting cloud formed at each lesion
site was imaged at 1 and 5 min. Early
and  late  images  of  each  lesion  were
presented serially in a randomized and
blind  fashion  to  an  observer  who
manually outlined the leakage area. The
graph  represents  adjusted  means
produced using a general linear model.
Leakage growth was significantly lower
in  NPD1-treated  animals  than  in
controls at both 7 and 14 days. Asterisks
denote level of statistical significance as
compared  to  vehicle  (*p<0.05;
**p<0.01; *** p<0.001).
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324Figure 4. Confocal microscopy of laser-induced choroidal neovascularization (CNV), showing extent of endothelial cell proliferation in control
animals. A, B: In this flatmount preparation of a control choroid at 7 days post treatment, the retina has been removed to expose a typical laser
lesion through Bruch’s membrane and into the choriocapillaris. A: Maximum projection (brightest voxel displayed for each Z-column) images
of immunolocalization for cytoskeleton (f-actin, green), nuclei (Heochst, blue), and endothelial cells (isolectin B4, red) are shown on the left,
along with a merged image of the three labels. The initial lesion (50 µm diameter) is apparent in the f-actin image, while endothelial cells
(capillaries) are seen to fill the site as proliferation proceeds. B: The same lesion as in A, presented as an orthogonal cut view. The large square
image represents a single layer in a confocal stack of images, as viewed above from the retina, with the three labels merged. Lateral views of
this image stack are shown at the top and to the right; the blue line in these views indicates the level within the stack of the view shown in the
square. The lateral view at the top is from the position of the green line in the large square; the lateral view to the right is from the position of
the red line in the large square. C, D: Images are organized the same as in A and B and depict a typical laser lesion of a control retina at 14
days post treatment. White circles represent the 50-µm-diameter initial laser lesion. Magnification bars equal 50 µm.
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325Figure 5. Confocal microscopy of laser-induced choroidal neovascularization (CNV) shows the extent of endothelial cell proliferation in
neuroprotecin D1 (NPD1)-treated animals. A, B: In this choroidal flatmount preparation from an NPD1-treated animal at 7 days post treatment,
the retina has been removed to expose a typical laser lesion through Bruch’s membrane and into the choriocapillaris. A: Maximum projection
images of immunolocalization for cytoskeleton (f-actin, green), nuclei (Heochst, blue), and endothelial cells (isolectin B4, red) are shown on
the left, along with a merged image of the three labels, as in Figure 4. B: The same lesion as in A, presented as an orthogonal cut view. The
large square image represents a single layer in a confocal stack of images, as viewed above from the retina, with the three labels merged.
Lateral views of this image stack are shown at the top and to the right; the blue line in these views indicates the level within the stack of the
view shown in the square. The lateral view at the top is from the position of the green line in the large square; the lateral view to the right is
from the position of the red line in the large square. C, D: Images, organized the same as in A and B, through a typical retinal laser lesion of
an NPD1-treated animal at 14 days post treatment. This lesion is presented at the right as an orthogonal cut view. White circles represent the
50-µm diameter initial laser lesion. Magnification bars are 50 µm.
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326corresponds to the RPE cell layer. At 14 days after laser injury,
labeled control choroidal flatmounts retained their extensive
endothelial cell lateral distribution and outward distribution
toward the retina (Figure 4B).
The  effect  of  NPD1  treatment  on  endothelial  cell
proliferation is evident from choroidal flatmounts. Confocal
imaging, as with the control groups, revealed cytoskeleton,
nuclei, and endothelial cell distributions. At 7 days after laser
treatment,  the  initial  lesion  was  visible  in  the  green
cytoskeleton channel, but some overcapping of the RPE cells
(outlined in green) was apparent. Again, the endothelial cells
ramified  within  the  lesion,  but  their  lateral  distribution
remained at about 50 µm, the diameter of the laser beam
(Figure 5A). There was an increase in the endothelial cell
lateral array to about 100 µm after 14 days (Figure 5B), but
the distribution of cells in the confocal stacks associated with
these lesions remained at one-third to one-half the size of those
found in the control groups at both 7 and 14 days.
Finally,  volumetric  analysis  of  isolectin-B4  revealed
endothelial cell volumes within each lesion at days 7 and 14.
Control lesions contained about 24,000 µm3 of endothelial cell
labels  at  day  7,  compared  to  NPD1  lesions  with  about
13,000  µm3,  which  represents  about  46%  less
neovascularization. The effect was more dramatic at 14 days
with about 20,000 µm3 of endothelial cell labels in control
groups and about 6,500 µm3 in the NPD1-treated group. This
represents a reduction in neovascularization volume at 7 and
14  days  post-laser  damage  by  about  50%  and  66%,
respectively (Figure 6).
DISCUSSION
In  the  present  study,  we  found  that  NPD1  significantly
reduced  the  extent  of  clinically  relevant  vascular  leakage
based on an established clinical grading scale. Importantly,
NPD1  was  administered  only  during  the  first  week  of
recovery, yet observations of NPD1-treated mice at day 14
demonstrated  continual  reduction  of  leakage  even  after
cessation of treatment. The effect of NPD1 was also observed
as a reduction in leakage rate, indicating that NPD1 had a
direct effect on the underlying dynamic pathogenic process
throughout  the  observation  period.  Ramification  of
endothelial  cells  displayed  a  similar  response  to  NPD1
treatment. Endothelial cell volume was significantly lower at
7  days  of  recovery  time,  and  as  with  leakage,  reduced
endothelial  cell  volume  was  not  simply  maintained  after
cessation of NPD1 treatment but continued to decrease with
further  recovery  time.  In  contrast,  vehicle  treatment
demonstrated only a modest reduction in clinical grading by
the end of the second week but failed to reduce leakage or
endothelial cell growth, indicating that the enduring inhibition
elicited by NPD1 was not a simple component of normal
resolution in the CNV model.
It is possible that the reduction of laser CNV leakage by
NPD1  occurs  through  inhibition  of  NF-κB  activation  and
COX-2 expression [27]. Retinal choroidal cells stimulated
with IL-1β resulted in increased COX-2 and ultimately VEGF
expression  [4].  Moreover,  we  have  shown  that  NPD1
downregulates IL-1β and TNF-α gene expression [29], which
are known to increase permeability of the pericyte/endothelial
cell complex [30]. Thus, NPD1 inhibition of CNV-associated
leakage may be the combinatorial result of reducing IL-1β and
TNF-α expression and inhibiting the activity of NF-κB, a
common downstream transcription factor of both pathways.
This  would  result  in  decreased  permeability  (vascular
leakage)  at  the  pericyte/endothelial  cell  complex  and  a
decrease in VEGF expression, which would reduce growth
and permeability of endothelial cells.
A second mechanism that could be involved in limiting
pathoangiogenesis in our laser CNV model is promotion of
cell survival. RPE cell integrity/viability is a key component
in  the  pathology  of  both  dry  and  wet  versions  of  AMD.
Promoting  RPE  cell  survival  could  play  a  role  in  re-
establishing  Bruch’s  membrane,  reforming  of  the  RPE
junctional  complex,  and  isolation  of  the  subretinal  space,
thereby preventing inappropriate molecular communication
Figure  6.  Comparison  of  endothelial  cell  volumes  within  laser-
induced lesion sites in choroids of control and neuroprotecin D1
(NPD1)-treated mice. Image stacks were obtained through each laser
lesion by confocal microscopy, and all voxels from the isolectin B4-
labeled endothelial cell channel with intensities above threshold were
summed for each layer. All layers throughout the stack were then
summed to give the total number of endothelial cell voxels per lesion
at 7 and 14 days following laser treatment. Volumes were calculated
by multiplying the total number of voxels by the voxel dimension
(0.45 µm×0.45 µm×0.45 µm). These volumes are represented by the
black (control) and white (NPD1-treated) bars. Asterisks denote level
of statistical significance as compared to vehicle (*p<0.05).
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327between the choroid and subretinal space. We have shown that
NPD1  potently  protects  the  RPE  from  oxidative  stress/
inflammatory-induced  apoptosis  [23,24].  NPD1  inhibits
inflammatory beta-amyloid-42 (Aβ-42)-induced apoptosis of
human neural cells composed of both neurons and glia [29],
and retinal ganglion cell apoptosis, triggered by optic nerve
damage, is prevented [31], suggesting that NPD1 may also
protect  photoreceptors  and  Müller  cells  from  CNV
inflammatory  signaling.  The  undamaged  periphery  of  the
initial laser lesion, or penumbra, may be subject to secondary
degeneration that results in a slow expansion of CNV. While
the RPE, Müller cells, and photoreceptors in this penumbra
are not obliterated by the laser damage, they may be severely
stressed, leading to enlargement of the lesion. Studies in a
mouse  CNV  model  illustrate  that  neutropenia  prevents
enlargement of retinal laser lesions, while lesions in wild-type
mice  double  in  size,  showing  that  neutrophils
(polymorphonuclear  leukocytes-PMNs)  promote  the
expansion  of  CNV  [32].  In  stroke,  a  key  reason  for  the
expansion of the penumbral region is infiltration of PMNs and
ameboid microglia [33]. Moreover, NPD1 prevented PMN
infiltration and markedly reduced penumbral damage in an
ischemia-reperfusion model [27]. This suggests that NPD1
may rescue cells in the penumbral region of laser-induced
CNV by directly promoting RPE survival and reducing PMN
infiltration. This may result in containment of the lesion and
preservation of the penumbral glia and neurons.
We  have  shown  that  NPD1  inhibits  choroidal
neovascularization.  The  efficacy  in  this  model  may  be  a
function of the combinatorial actions of NPD1 in protecting
cells  from  apoptosis  while  downregulating  the  pro-
inflammatory  cytokines  TNF-α  and  IL-1β,  possibly  by
inhibiting NF-κB activity and reducing COX-2, leading to
decreased VEGF expression. Overall NPD1 may contribute
to fine tuning the induction of the resolution phase of the
inflammatory  response.  The  anti-angiogenic  and
neuroprotective  actions  of  NPD1  highlight  its  potential
applicability in treating wet AMD and diabetic retinopathy,
and the current results show NPD1 to be at least as efficacious
as, if not more than, other interventions explored in this model.
Based on our understanding of the pathology of the CNV
model, the results imply the potential suitability of NPD1 for
the treatment of other neural (e.g., Alzheimer disease) and
non-neural (e.g., asthma) inflammatory diseases.
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